BioSpace News Archive

The prevalence of chronic diseases is rising substantially. This aspect may serve as a prominent growth generator for the global ambulatory surgical centers market across the forecast period of 2019-2029.

- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced that Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics, will present at the upcoming 10 th Annual SVB Leerink Healthcare Conference on Thursday, February 25, 2021, at 9:20 a.m. ET.

OrthoPediatrics and ApiFix are committed to helping patients with adolescent idiopathic scoliosis and their families make informed decisions about treatment options in partnership with their physiotherapist and pediatric orthopedic specialist

Infinity Pharmaceuticals, Inc. announced the closing of the sale of 24,150,000 shares of its common stock at a public offering price of $3.80 per share in its previously announced underwritten public offering, including 3,150,000 shares sold upon the exercise in full of a 15% over-allotment option by the underwriters.

CB Scientific, Inc., is pleased to provide an update on the progress and achievements we have made since transitioning to the Ambulatory Remote Cardiac Monitoring market in June of 2020.

Generation Bio Co., an innovative genetic medicines company creating a new class of gene therapy, announced that Ron Cooper has been appointed to its Board of Directors.

Cytokinetics, Incorporated announced that Muna Bhanji has been appointed to the company’s Board of Directors.

Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced plans to advance FX201 into the high dose cohort of the Phase 1 dose-escalation trial.

Steve Kelsey, M.D., President, Research and Development, to Present its Pioneering RAS(ON) Inhibitors and Participate in Panel Discussion

Molecular Templates, Inc. (Nasdaq: MTEM) (the “Company” or “Molecular”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics for cancer, today announced the pricing of its underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $12.65 per share.